@article{614cdcc48d424fa39ea985c5a01eedc1,
title = "Resolving delayed sleep-wake phase disorder with a pandemic: two case reports",
abstract = "Two patients with delayed sleep-wake phase disorder (DSWPD) demonstrated improvement in sleep quality and duration, reduction in symptoms, and elimination of the need for hypnotic or stimulant medications after changing their sleep schedules in response to the coronavirus disease 2019 (COVID-19) pandemic lockdown work schedule changes. These cases highlight the impact of work schedules on patient health and raise questions about approaches to workplace schedule requirements postpandemic.",
keywords = "COVID-19, circadian, delayed sleep-wake phase, pandemic, sleep diary",
author = "Epstein, {Lawrence J.} and Alice Cai and Klerman, {Elizabeth B.} and Czeisler, {Charles A.}",
note = "Funding Information: All authors have seen and approved this manuscript. Work for this study was performed at Brigham and Women{\textquoteright}s Hospital. Supported in part by National Institute of Occupational Safety and Health (R01-OH-011773). Dr. Epstein is a consultant to AIM Specialty Health, eviCore Healthcare, Somnoware Healthcare Systems, and the American Academy of Sleep Medicine. Dr. Klerman is a consultant to Sanofi-Genzyme; National Sleep Foundation; Puerto Rico Science, Technology and Research Trust; and her significant other owns Chronsulting. Dr. Czeisler is or was a paid consultant to Bose, Boston Celtics, Boston Red Sox, Cephalon, Institute of Digital Media and Child Development, Klarman Family Foundation, Jazz Pharmaceuticals PLC Inc., Merck, National Sleep Foundation, Physician{\textquoteright}s Seal, Purdue Pharma, State of Washington Board of Pilotage Commissioners, Teva Pharma Australia PTY Ltd., Tencent Holdings Ltd., and Vanda Pharmaceuticals, in which he also holds an equity interest. Dr. Czeisler and/or the division that he directs receive or have received research/education/quality improvement program support from the AFOSR, CDC/ NIOSH, CDC Foundation, with funding provided by BNY Mellon, Cephalon, Dayzz Live Well Ltd., Delta Airlines, DOD, FAA, Harmony Biosciences LLC, Jazz Pharmaceuticals PLC Inc., Johnson & Johnson, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, ONR, NASA, NCATS, NFL Charities, NHLBI, NIA, NIGMS, Optum, Philips Respironics Inc., Puget Sound Pilots, Regeneron Pharmaceuticals, ResMed, San Francisco Bar Pilots, Sanofi SA, Schneider, Simmons, Sysco, Teva Pharmaceuticals Industries Ltd., Vanda Pharmaceuticals, and WHOOP, Inc. and has received support for attending meetings and/or travel from Tencent Holdings Ltd., Aspen Brain Institute, Bloomage International Investment Group, Inc., Stanley Ho Medical Development Foundation, German National Academy of Sciences, National Safety Council, and the National Sleep Foundation. In addition, since 1985, Dr. Czeisler has served as an expert witness in a number of legal cases, including those involving Aegis Chemical Solutions, Amtrak, Bombardier, C&J Energy, Casper Sleep Inc., Columbia River Bar Pilots, Dallas Police Association, Enterprise Rent-A-Car, Fedex, Greyhound, PAR Electrical Contractors Inc., Purdue Pharma, Schlumberger Technology Corp., Union Pacific Railroad, UPS, and Vanda Pharmaceuticals. Dr. Czeisler serves as the incumbent of a professorship endowed by Cephalon and receives royalties from McGraw-Hill and from Philips Respironics (for the Actiwatch-2 and Actiwatch Spectrum devices). Dr. Czeisler{\textquoteright}s interests were reviewed and managed by Brigham and Women{\textquoteright}s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. Publisher Copyright: {\textcopyright} 2022 American Academy of Sleep Medicine. All rights reserved.",
year = "2022",
month = jan,
day = "1",
doi = "10.5664/jcsm.9526",
language = "English",
volume = "18",
pages = "315--318",
journal = "Journal of Clinical Sleep Medicine",
issn = "1550-9389",
publisher = "American Academy of Sleep Medicine",
number = "1",
}